HIGH

RC Outsourcing Bevacizumab Intravitreal Syringe Recall 2,669 Units in 2025 Over Sterility Concerns

RC Outsourcing recalled 2,669 bevacizumab intravitreal syringes distributed nationwide to hospitals and clinics. The recall cites a lack of assurance of sterility. Stop using the product immediately and contact RC Outsourcing or your healthcare provider for guidance. Recall notices will be sent by letter.

Quick Facts at a Glance

Recall Date
September 22, 2025
Hazard Level
HIGH
Brand
RC Outsourcing
Category
Health & Personal Care
Sold At
Multiple Retailers
Geographic Scope
1 states
At-Risk Groups
GENERAL, PREGNANT, GENERAL

Hazard Information

Lack of assurance of sterility.

What You Should Do

Consumers and healthcare providers should stop using this product immediately. Contact RC Outsourcing, LLC or your healthcare provider for guidance. Notification method: Letter

Get instant alerts for Health & Personal Care recalls

Be the first to know. Free instant alerts to your inbox.

No spamUnsubscribe anytime

About This Product

Bevacizumab intravitreal injections are used to treat retinal diseases in adults and are prepared for hospital or office use. They are administered by ophthalmologists in a clinical setting.

Why This Is Dangerous

A lack of sterility can result in contamination and eye infections, including serious conditions like endophthalmitis, requiring medical care.

Industry Context

This recall is not part of a broader industry pattern.

Real-World Impact

Hospitals and clinics must review stock, pause administrations, and coordinate with suppliers. The recall involves 2,669 syringes distributed nationwide, potentially affecting patient care workflows and budgets.

Practical Guidance

How to identify if yours is affected

  1. Check lot numbers on packaging and syringes against the recalled lots: 20250708-768A26, 20250715-944DF2, 20250722-55C603, 20250722-5DC113.
  2. Inspect remaining stock to ensure no recalled lots remain in use.
  3. Quarantine any implicated lots per facility protocol.
  4. Communicate with RC Outsourcing LLC for instructions and record all steps taken.

Where to find product info

FDA enforcement page for D-0003-2026 and recall notices: https://www.accessdata.fda.gov/scripts/enforcement/enforce_rpt-Product-Tabs.cfm?recall_number=D-0003-2026

What timeline to expect

Recall processing timelines vary; follow RC Outsourcing guidance. Typical recall-related refunds or replacements, when offered, can take several weeks

If the manufacturer is unresponsive

  • Escalate to FDA MedWatch for safety concerns.
  • Document all communications and consider legal counsel if needed.

How to prevent similar issues

  • Verify sterile, FDA-licensed suppliers for intravitreal medications.
  • Require traceability of lots and date codes for all ophthalmic injections.
  • Maintain strict cold-chain handling for refrigerated products.
  • Establish a single point of contact in purchasing for recalls to speed action.

Documentation advice

Retain all recall notices, packaging photos, lot numbers, communication with RC Outsourcing LLC, and records of stock disposition.

Product Details

Bevacizumab intravitreal syringe, 0.25 mL total volume (1.75 mg/0.07 mL). Lot numbers being recalled: 20250708-768A26, 20250715-944DF2, 20250722-55C603, 20250722-5DC113. Sold to hospitals and clinics nationwide in the United States. Recall date: 2025-09-22. Quantity: 2,669 syringes. Price: Unknown.

Reported Incidents

No injuries or incidents have been reported.

Key Facts

  • 2,669 syringes recalled
  • Lot numbers: 20250708-768A26; 20250715-944DF2; 20250722-55C603; 20250722-5DC113
  • Distributed nationwide to hospitals/clinics
  • Sterility concerns require immediate action

Safety Guide

Not sure what to do next? Our guide walks you through the process step by step.

Read: What to Do When You Find a Recalled Product

Get Alerts for Health & Personal Care Recalls

Get instant alerts for recalls that affect you. Free forever.

Safety Assessment

Risk LevelHIGH
Severity Score
8/ 10
Affected Groups
GENERALPREGNANTGENERALELDERLYPREGNANT
Injury Types
OTHER

Product Classification

Product TypeBevacizumab Intravitreal Syringe (0.25 mL; 1.75 mg/0.07 mL)
Sold At
Multiple Retailers

Product Details

Model Numbers
20250708-768A26
20250715-944DF2
20250722-55C603
20250722-5DC113
Affected States
ALL
Report Date
October 15, 2025
Source Agency
FDA - Drug Safety
Recall Status
ACTIVE

Related Recalls

Vehicles & Parts
HIGH

Mazda CX-70 Recall 2025 for Powertrain Control Module Software May Lose Drive Power

Mazda North American Operations is recalling 2024 CX-90 and 2025 CX-70 SUVs sold through Mazda dealers. The PCM and ECM software can illuminate malfunction indicator lights and cause a loss of drive power, increasing crash risk. Owner notification letters were mailed December 19, 2024, and Mazda will reprogram the PCM and ECM at no charge.

Mazda
Loss of
Read more
Vehicles & Parts
HIGH

Nissan Kicks 2025 Certification Label Recall for GVWR/GAWR Errors (PD136, PMA47)

Nissan North America is recalling certain 2025 Nissan Kicks vehicles sold through Nissan dealers nationwide. The certification label may print incorrect GVWR and GAWR values, risking overload. Some SR trims with a 19-inch wheel package may display an incorrect wheel size on the label, and owners should contact their Nissan dealer to arrange replacement labels.

Nissan
An overloaded
Read more
Vehicles & Parts
HIGH

Chrysler Pacifica Radio Recall 2025 Over Rearview Camera Display Issue

Chrysler is recalling 2024-2025 Pacifica minivans after a radio installed during production could fail to display the rearview camera image. Dealers will replace the radio at no cost. Owner letters were mailed August 7, 2025. Contact Chrysler customer service at 800-853-1403 for details.

Chrysler
A rearview
Read more